Ultragenyx Pharmaceutical Inc  

(Public, NASDAQ:RARE)   Watch this stock  
Find more results for RARE
61.01
-0.42 (-0.68%)
After Hours: 61.01 0.00 (0.00%)
Jul 28, 4:56PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 60.33 - 63.17
52 week 46.52 - 133.40
Open 61.27
Vol / Avg. 0.00/829,863.00
Mkt cap 2.56B
P/E     -
Div/yield     -
EPS -4.63
Shares 39.02M
Beta     -
Inst. own 96%
Aug 11, 2016
Q2 2016 Ultragenyx Pharmaceutical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 14, 2016
Ultragenyx Pharmaceutical Inc Presents Phase 3 Data for Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
Jun 21, 2016
Ultragenyx Pharmaceutical Inc at JMP Securities Life Sciences Conference
Jun 17, 2016
Ultragenyx Pharmaceutical Inc Annual Shareholders Meeting (Estimated)
Jun 9, 2016
Ultragenyx Pharmaceutical Inc Annual Shareholders Meeting
Jun 8, 2016
Ultragenyx Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 7, 2016
Ultragenyx Pharmaceutical Inc at Jefferies Healthcare Conference
May 11, 2016
Ultragenyx Pharmaceutical Inc at Bank of America Merrill Lynch Health Care Conference
May 9, 2016
Q1 2016 Ultragenyx Pharmaceutical Inc Earnings Call
May 9, 2016
Q1 2016 Ultragenyx Pharmaceutical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -39.05% -38.45%
Return on average equity -41.45% -40.67%
Employees 289 -
CDP Score - -

Address

60 Leveroni Ct
NOVATO, CA 94949-5746
United States - Map
+1-415-4838800 (Phone)
+1-415-4838810 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

Officers and directors

Emil D. Kakkis M.D. Ph.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Shalini Sharp Senior Vice President, Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Karah Parschauer Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Sunil Agarwal M.D. Chief Medical Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Jayson Donald Alexander Dallas Senior Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Dennis Huang Chief Technical Operations Officer and Senior Vice President
Bio & Compensation  - Reuters
Thomas Kassberg Senior Vice President, Chief Business Officer
Age: 54
Bio & Compensation  - Reuters
John Pinion Chief Quality Operations Officer and Senior Vice President, Analytical Sciences and Research
Bio & Compensation  - Reuters
William E. Aliski Independent Director
Age: 67
Bio & Compensation  - Reuters
Lars G. Ekman M.D. Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters